2-Oxoindoline-based hydroxamic acids: novel HDAC inhibitors with promising anticancer activity
Open Access
- 12 August 2026
- journal article
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (37) , 40085-40104
Abstract
Histone deacetylase (HDAC) inhibitors are important epigenetic anticancer agents that regulate gene expression, induce cell cycle arrest, and promote apoptosis.Keywords
This publication has 49 references indexed in Scilit:
- Molecular Properties That Influence the Oral Bioavailability of Drug CandidatesJournal of Medicinal Chemistry, 2002
- Simple Selection Criteria for Drug-like Chemical MatterJournal of Medicinal Chemistry, 2001
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1Advanced Drug Delivery Reviews, 2001
- Prediction of Drug Absorption Using Multivariate StatisticsJournal of Medicinal Chemistry, 2000
- The Design of Leadlike Combinatorial Libraries.1999
- Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitorsNature, 1999
- A Knowledge-Based Approach in Designing Combinatorial or Medicinal Chemistry Libraries for Drug Discovery. 1. A Qualitative and Quantitative Characterization of Known Drug DatabasesJournal of Combinatorial Chemistry, 1998
- Histone deacetylases, acetoin utilization proteins and acetylpolyamine amidohydrolases are members of an ancient protein superfamilyNucleic Acids Research, 1997
- VMD: Visual molecular dynamicsJournal of Molecular Graphics, 1996
- Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening.1992